Blog

Small-Cap Surges: A Deep Dive Into Shelter Pharma’s 12% Jump

Small-Cap Surges: A Deep Dive Into Shelter Pharma’s 12% Jump

With the general indices suffering a bloodbath of 1,300 points in the past week, one weirdo had surfaced on the ticker tape. With the launch of a new product line, the share price of Shelter Pharma gained 12% due to the company's strategic move. Most of the market was going on the defensive posture of capital protection while this small-cap pharmaceutical company was a reminder that in the equity world, Alpha is usually located where the fundamentals find a growth catalyst.
 
The price actions are interesting to me as a Chartered Accountant, having audited balance sheets and done due diligence on emerging mid-sized companies for more than 25 years. They represent the "micro" beating the "macro". Let's break this down, not as a piece of news, but as a case example of market valuation, product life cycle, and investor sentiment.
 
The Catalyst

Product Launch as a Valuation Driver
For small cap companies such as Shelter Pharma, the stock price is frequently a function of the company's “probabilistic value” and not its “intrinsic value,” as often is discussed by market analysts. This is a marketing event not just for the company, but also for the auditor since a new product launch may signal an anticipated change in the company's future cash flow forecast.
 
Once the pharmaceutical company has managed to get a new product to market, it is a sign to the institutional and retail community of three important items:
 
  • Technology Advantage: It demonstrates the capability of developing products that others are not doing.
 
  • Intellectual Property Protection: It ensures that investments in R&D are maturing into an asset which can generate revenue. 
 
  • Market diversification: It recommends that the company is diversifying its product portfolio, decreasing their reliance upon a couple of “star” products, and decreasing concentration threat. 
 
  • Margin Improvement: When a new product is launched, particularly in a niche market, it may have a higher margin in its early stages than a generic product that has existed for years. 
 
Within the due diligence process we conduct with firms we are particularly interested in the ‘Product Pipeline Velocity'. A company that has proven to be able to bring new things to market and grow them is always worth a higher multiple than a company that is not growing and is simply just bigger but older.
 
This 12% Surge is a Technical Fundamental Intersection.
There are only a few large jumps that can be made in a single session, such as the 12% gain. Investors are seeking “defensive growth” in the present turbulent times when the Rupee is trading at 95/$ and crude is at $105. For the pharmaceutical industry, the product is always in demand, making it a traditional insurance policy against economic downturn.
 
  1. Liquidity and Volume Analysis: For a small-cap stock, these big swings are usually accompanied by a huge increase in volume. As a CA, I always hesitate to "price discovery without 'volume support'". When volume is 5x the 30-day average, it means that desks are being opened at institutional or larger levels of HNI desks. This gives traders a price "floor" to keep the rise in check. 
     
  2. Operating Leverage: Small-cap companies have a high degree of operating leverage. That means that with a little extra revenue (a new product) there is a disproportionate increase in bottom-line (profit) revenue because fixed costs are sunk. That's why the stock price is so volatile when news of this "Delta" in profitability gets released. 
 
A word of warning: Risk Management
 
A 12% increase is appealing but in my 25 years in a trade, I have learned that any upswing in trade volume comes with a very thorough examination of the risks. For our 500+ clients across India, we always emphasise the following "Checklist for Small-Cap Investing":
 
  • Execution Risk: Launching is just half the challenge! The question really is 'Go to Market'. Does the company have the distribution network in place to get this product to the shelves? 
 
  • Regulatory Environment: The USFDA's shadow and Indian drug controller's shadow are always present in Pharma. A 12% gain in minutes can be lost due to any compliance problem. As CAs, we don't only think about ‘Financial Health’ but also ‘Compliance Health’. 
 
  • Working Capital Stress: A lot of investment is needed in the inventory and marketing of new products. One needs to watch to see if the company is overextending itself by trying to grow at this rate. When the debt-to-equity ratio begins to rise, the "growth" could very well be eroding shareholder value in the long run. 
 
This is the Strategic Advice for our HNI clients.
At all our offices, from Pune to Kolkata, we are pushing our clients to be “tactically aggressive”. Do not sell off with the first 10% gain when you have small cap pharma stocks with good fundamentals, such as product launches, in your portfolio. Instead, consider the relative strength indicator (RSI) and that the company's debts are not too large. In a market environment that is in decline, these individual "growth stories" are the hotspots of market liquidity that hold the rest of the market.
 
Conclusions 

The " Audit" of Opportunity
Pockets of massive opportunity abound even in a “bloodbath” market, as the 12% rise in Shelter Pharma has demonstrated. It helps to strengthen the importance of sector-specific knowledge. The rule of the game is the same wherever we go: We trust the information, we check the catalyst and we always guard the downside, no matter whether we're doing a small cap due diligence report on Shelter or a deep dive on a more established company. The crash yesterday was a reminder of risk, but the small cap surge was a reminder of reward today. Maintain balance, continue to be audited?